Robust group sequential designs for trials with survival endpoints and delayed response.

Ghosh, Pranab; Ristl, Robin; König, Franz; Posch, Martin; Jennison, Christopher; Götte, Heiko; Schüler, Armin; Mehta, Cyrus

Ghosh, Pranab; Ristl, Robin; König, Franz; Posch, Martin; Jennison, Christopher; Götte, Heiko; Schüler, Armin; Mehta, Cyrus.

Afiliação

Ghosh P; Pfizer Corporation, Cambridge, MA, USA.
Ristl R; Section for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
König F; Section for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
Posch M; Section for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
Jennison C; Department of Mathematical Statistics, University of Bath, Bath, UK.
Götte H; Merck AG, Darmstadt, Germany.
Schüler A; Merck AG, Darmstadt, Germany.
Mehta C; Cytel Inc., Cambridge, MA, USA.

Biom J ; 64(2): 343-360, 2022 02.

Article em En | MEDLINE | ID: mdl-34935177

Assuntos

Vacinas Anticâncer; Neoplasias; Vacinas Anticâncer/uso terapêutico; Humanos; Oncologia/métodos; Neoplasias/tratamento farmacológico; Nivolumabe/uso terapêutico; Modelos de Riscos Proporcionais; Ensaios Clínicos Controlados Aleatórios como Assunto; Análise de Sobrevida

Palavras-chave

Fleming-Harrington test; cancer immunology; delayed response; group sequential design; immuno-oncology; late separation of survival curves; log-rank test; max-combo test; modestly weighted log-rank test; nonproportional hazards

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google